Lakeland Surgical & Diagnostic Center Sets New Standard of Care for Environmental Cleanliness & Reduces Infection Rates with Help from a Germ-Zapping Robot

Lakeland, FL – September 26, 2018 – In its ongoing commitment to patient safety, Lakeland Surgical & Diagnostic Center, LLP (LSDC) was the first Ambulatory Surgical Center (ASC) in Florida to deploy a state-of-the-art LightStrike™ disinfection device. The Xenex LightStrike Germ-Zapping Robot™ quickly destroys the pathogens in Operating Rooms that can cause infections and pose a risk to patient safety. Since deploying two robots at the end of 2017, LSDC has seen a reduction in Surgical Site Infection (SSI) rates at both of its surgical locations.

“LSDC has a rigorous infection prevention program in place. Recognizing that the pathogens that can pose a risk to patient safety are becoming resistant to cleaning chemicals, we enhanced our disinfection efforts with the addition of LightStrike robots.  The portable and powerful UV disinfection robot quickly destroys microscopic pathogens lurking on surfaces in the ORs that we can’t see,” said Nikki Williams RN CNOR, Director of Operating Rooms at LSDC. “When it comes to infections, our goal is zero, and that’s why we’re thrilled that we’ve seen a reduction in our SSI rates, which were already very low.”

The LightStrike robots harness the power of pulsed xenon to create intense, full spectrum ultraviolet (UV) light that quickly and effectively destroys hard to kill pathogens that can cause infections such as Staphylococcus aureusEnterococcus, Klebsiella and Pseudomonas, which are capable of living on Operating Room (OR) surfaces from 1.5 hours to more than 30 months, even after it has been cleaned with traditional methods. LSDC is using its robots to disinfect patient rooms, treatment areas, and operating rooms after the day’s procedures are complete.

Always at the forefront of patient care and cutting edge technology, the two LSDC locations are the only facilities in Lakeland currently using this innovative technology. The LightStrike robots have been credited in peer-reviewed studies by numerous healthcare facilities for helping them reduce their Clostridium difficile (C.diff), Methicillin-resistant Staphylococcus aureus (MRSA) and surgical site infection rates 46{a7dbd90b9ffe087840aba08710c78edd3b62ca0d1e957cc3862d95b1204bafc3}-100{a7dbd90b9ffe087840aba08710c78edd3b62ca0d1e957cc3862d95b1204bafc3}.

“Lakeland Surgical & Diagnostic Center is committed to excellence. They are continually evaluating new technologies that can enable them to provide the best care to the patients they serve, and we are honored that our disinfection robots are part of their comprehensive infection prevention program. As a result of their success in bringing down their already low SSI rates, we are recognizing them as a Visionary facility,” said Irene Hahn, vice president of sales and account management at Xenex.

As a result of their commitment to patient safety and robust infection prevention program, Xenex has designated Lakeland Surgical & Diagnostic Center as a Visionary ASC. Visionary facilities are defined as those that 1. Make patient safety a top priority; 2. Seek out and implement technologies with multiple proven outcomes published in peer reviewed publications; 3. Follow manufacturer recommended best practices; 4. Publicize and share results to improve best practices for all healthcare facilities; 5. Openly share their data for their benefit and the benefit of all mankind.

Xenex Disinfection Systems

Xenex LightStrike Germ-Zapping Robots are used for the advanced disinfection of healthcare facilities. Due to its speed and ease of use, the Xenex system has proven to integrate smoothly into healthcare cleaning operations. Xenex’s mission is to save lives and reduce suffering by destroying the deadly pathogens and superbugs that cause hospital acquired infections (HAIs). The company is backed by well-known investors that include EW Healthcare Partners, Piper Jaffray Merchant Services, Malin Corporation, Battery Ventures, Tectonic Ventures, Targeted Technology Fund II and RK Ventures. For more information, visit



Credit Kim Manganello